Skip to main content

Technical and commercial feasibility of two CD2-based T cell therapies against CLL

Project description

Novel T cell therapies against lymphocytic leukaemia

Chronic lymphocytic leukaemia (CLL) is a haematological malignancy that affects B lymphocytes, which produce antibodies. CLL remains incurable, emphasising the need for effective treatments. Emerging evidence indicates a perturbation in the T cell compartment in CLL with phenotypic and functional defects as well as an active role in cancer development and evolution. As a result, T cell-based treatments such as chimeric antigen receptor T cell (CAR-T) therapy and poly-specific antibodies have shown poor clinical efficacy. Funded by the European Research Council, the CATCH project proposes to test the technical and commercial feasibility of a novel combinatorial approach of endogenous T cell activation in CLL patients. Researchers will combine CAR-T therapy and tri-specific antibodies to overcome T cell dysfunction and stimulate an immune response.

Coordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Net EU contribution
€ 150 000,00
Address
Meibergdreef 15
1105AZ Amsterdam
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Other funding
No data